IL2 and melanoma: A more recent study, performed in Israel, found that 50% of advanced, chemotherapy and IL-2 refractory melanoma patients achieved radiologic response to short-term cultured bulk tumour-infiltrating lymphocyte therapy with a tolerable toxicity profile [32].